SML1433
AMD3465
≥98% (HPLC), CXCR4 antagonist, powder
别名:
AMD 3465, GENZ-644494, N-[[4-(1,4,8,11-Tetraazacyclotetradec-1-ylmethyl)phenyl]methyl]-2-pyridinemethanamine hexahydrobromide
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
产品名称
AMD3465, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to light brown
solubility
H2O: 25 mg/mL, clear
storage temp.
−20°C
SMILES string
N3(CCNCCCNCCNCCC3)Cc1ccc(cc1)CNCc2ncccc2
InChI
1S/C24H38N6/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2
InChI key
CWJJHESJXJQCJA-UHFFFAOYSA-N
Biochem/physiol Actions
AMD3465 is also termed as{N-[1,4,8,11-tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine}. It controls oncogenic signaling and invasiveness in vitro. It inhibits breast cancer growth and metastasis in vivo. As a chemokine receptor 4 (CXCR4) antagonist, AMD3465 is ten times more efficient than bicyclam AMD3100.
AMD3465 is a highly selective chemokine receptor CXCR4 antagonist with antiviral and anticancer activity.
AMD3465 is a highly selective chemokine receptor CXCR4 antagonist with antiviral and anticancer activity. The chemokine receptor CXCR4 is expressed on a wide variety of leukocytes and is the predominant receptor for stromal cell-derived factor-1 (SDF1, CXCL12) in addition to acting as a co-receptor for HIV entry into cells. AMD3465 blocks surface binding of CXCL12 (SDF-1α). AMD3465 is an antagonist of SDF-1 ligand binding (K(i) of 41.7+/-1.2 nM). AMD3465 was found to halt the progression of an agressive childhood blood cancer, T-cell acute lymphoblastic leukemia (T-ALL), within two weeks of starting treatment in an animal model.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable